GlobeNewsWire
14 Jun 2026, 14:00 UTC · 13w ago
Verdict
Headline takes no side. We score MLYS +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Lorundrostat is currently under FDA review with a PDUFA target date of December 22, 2026.
More positive than 91% of claims this week
Proteomic analysis showed lorundrostat significantly reduced 6 of 11 causal risk biomarkers for heart failure, including NT-proBNP.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of claims this week
Data from Phase 3 Launch-HTN and Phase 2b Advance-HTN trials suggest the drug favorably modulates pathways reducing harmful fibrosis.
More positive than 65% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company presented positive late-breaking data showing lorundrostat is associated with significant reductions in heart failure risk biomarkers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
20h ago
+21.5%
Price agrees with the score
$28.71 vs $23.62 close before publication (Jun 12) · not market-adjusted
MLYS chart →
